NCT04265872 2026-02-12Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBCBaylor Research InstitutePhase EARLY_PHASE1 Recruiting20 enrolled
NCT07341867 2026-01-14Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeDana-Farber Cancer InstitutePhase 1 Not yet recruiting90 enrolled